LEVACT

This brand name is authorized in Austria, Cyprus, Spain, Netherlands, Poland, Tunisia

Active ingredients

The drug LEVACT contains one active pharmaceutical ingredient (API):

1 Bendamustine UNII 981Y8SX18M - BENDAMUSTINE HYDROCHLORIDE

Bendamustine is an alkylating antitumour agent with unique activity. The antineoplastic and cytocidal effect of bendamustine is based essentially on a cross-linking of DNA single and double strands by alkylation. As a result, DNA matrix functions and DNA synthesis and repair are impaired. Read about Bendamustine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01AA09	Bendamustine	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01A Alkylating agents → L01AA Nitrogen mustard analogues
Discover more medicines within L01AA09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 72571
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 98450, 98469
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100232322
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 16613011H, 16613012H